We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Myriad Genetics, Inc. (MYGN - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $27.23 to $31.51in the past one-month time frame, witnessed a sharp increase on Friday.
The company has seen a mixed track record when it comes to estimate revision of one increase and no decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Myriad Genetics currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is positive.
Is MYGN going up? Or down? Predict to see what others think: Up or Down
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
Image: Bigstock
Myriad Genetics (MYGN) Catches Eye: Stock Jumps 6.9%
Myriad Genetics, Inc. (MYGN - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $27.23 to $31.51in the past one-month time frame, witnessed a sharp increase on Friday.
The company has seen a mixed track record when it comes to estimate revision of one increase and no decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Myriad Genetics currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is positive.
Myriad Genetics, Inc. Price
Myriad Genetics, Inc. Price | Myriad Genetics, Inc. Quote
Investors interested in the Medical - Biomedical and Genetics industry may consider Acorda Therapeutics, Inc. , which also has a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Is MYGN going up? Or down? Predict to see what others think: Up or Down
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>